泰格医药(03347.HK):拟认缴2亿元参投云锋超萃基金
格隆汇 8 月 29日丨泰格医药(03347.HK)公布,公司所属投资平台杭州泰格股权投资合伙企业(有限合伙)拟参与投资云锋超萃基金(“合伙企业”)。该基金认缴出资总额为人民币10亿元,公司拟认缴出资人民币2亿元。
合伙企业将主要对大健康领域(包括但不限于医疗、医药、器械、服务、物联网医疗和医疗IT)进行价值投资。
此次投资主体杭州泰格股权投资合伙企业(有限合伙)成立于2016年4月22日,系公司专业投资平台,由两名合伙人共同发起设立,执行事务合伙人为上海泰格医药科技有限公司,有限合伙人为杭州泰格医药科技股份有限公司。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.